Literature DB >> 17188007

Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse.

Yann Mikaeloff1, Guillaume Caridade, Béatrice Husson, Samy Suissa, Marc Tardieu.   

Abstract

To date, there is no available epidemiological study about prognostic factors of acute disseminated encephalomyelitis (ADEM) in children, using a cohort of patients with homogenous inclusion criteria. We aimed to evaluate prognostic factors for relapse after ADEM in children. A total of 132 children from the French National KIDSEP Neuropediatric Cohort (mean age at onset: 6+/-3.3 years; mean follow-up: 5.4+/-3.3 years; lost to follow-up: 10%). ADEM diagnosis was considered in a previously healthy patient acutely presenting more than one neurological deficit, change in mental state and MRI alterations including white matter changes. We used multivariate survival analysis (Cox model) evaluating the prognostic value of baseline clinical, biological and MRI covariates, for the occurrence of a second attack. Twenty-four (18%) of included patients had a second attack. An increased risk of relapse was associated with optic neuritis (hazard ratio, 5.23; 95% CI, 2-13.65), familial history of central nervous system inflammatory demyelination (7.79; 1.54-39.5), Barkhof multiple sclerosis (MS) criteria on MRI (2.52; 1.04-6.12) and no neurological sequelae after first attack (3.79; 1.12-12.85). Clinical and MRI prognostic factors for relapse in ADEM may contribute to an early distinction between monophasic and relapsing disease, which may be related to MS.

Entities:  

Mesh:

Year:  2006        PMID: 17188007     DOI: 10.1016/j.ejpn.2006.11.007

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  40 in total

Review 1.  Imaging in Pediatric Demyelinating and Inflammatory Diseases of the Brain- Part 1.

Authors:  Sniya Valsa Sudhakar; Karthik Muthusamy; Sunithi Mani; Sridhar Gibikote; Manohar Shroff
Journal:  Indian J Pediatr       Date:  2015-12-04       Impact factor: 1.967

2.  Recurrent pseudotumoral hemicerebellitis: neuroimaging findings.

Authors:  Kader K Oguz; Goknur Haliloglu; Dursun Alehan; Meral Topcu
Journal:  Pediatr Radiol       Date:  2008-01-08

Review 3.  Hashimoto's encephalopathy : epidemiology, pathogenesis and management.

Authors:  Ramon Mocellin; Mark Walterfang; Dennis Velakoulis
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Sorting through the pediatric MS spectrum with brain MRI.

Authors:  Dorothée Chabas; Daniel Pelletier
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

Review 5.  Pediatric multiple sclerosis.

Authors:  E Ann Yeh; Tanuja Chitnis; Lauren Krupp; Jayne Ness; Dorothée Chabas; Nancy Kuntz; Emmanuelle Waubant
Journal:  Nat Rev Neurol       Date:  2009-10-13       Impact factor: 42.937

6.  Pediatric multiple sclerosis.

Authors:  Yashma Patel; Vikram Bhise; Lauren Krupp
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

7.  Neuroradiological evaluation of demyelinating disease.

Authors:  Jan-Mendelt Tillema; Istvan Pirko
Journal:  Ther Adv Neurol Disord       Date:  2013-07       Impact factor: 6.570

8.  Recruitment criteria for acute disseminated encephalomyelitis studies: the need for consensus.

Authors:  E Marchioni; G Bono; E Tavazzi; A Antinori; L Minoli; M Ceroni
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

Review 9.  Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.

Authors:  J Nicholas Brenton; Brenda L Banwell
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

10.  No evidence for impairment of venous hemodynamics in children or young adults with pediatric-onset multiple sclerosis.

Authors:  S Laughlin; C K Macgowan; J Traubici; K Chan; S Khan; D L Arnold; R A Marrie; B Banwell
Journal:  AJNR Am J Neuroradiol       Date:  2013-07-18       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.